Objective To investigate the effects of Flupentixol and Melitracen Tablets on anxious-depressive symptoms in patients with coronary artery disease. Methods 120 patients with coronary artery disease associated with anxious-de-pressive symptoms were randomly divided into control group (n =63) and treatment group (n =57). All the patients received conventional therapy and nursing, while Flupentixol and Melitracen Tablets therapy was added to the patients in treatment group. 2 weeks after treatment, the relief condition of symptoms, changes of SAS and SDS scores, and arrhythmia were compared between the two groups. Results SAS and SDS scores in both groups significantly decreased after treatment, and the differences were significant before and after treatment (P ＜0. 05). Both scores in treatment group were lower than those in the control group (P ＜0. 05). The remission rate of chest pain in the treatment group was obviously higher than that in the control group, and the difference was significant (P ＜ 0. 05). The number of ventricular premature beats in the treatment group before and after treatment were (834.8 ± 396. 7)/24 h and (638.5 ± 232.0)/24h respectively, and there was significant difference before and after treatment (P ＜ 0. 05). Conclusion Flupentixol and Melitracen Tablets can significantly alleviate symptoms of anxious-depressive and chest pain in patients with coronary artery disease without increasing arrhythmia in a short term.%目的 探讨氟哌噻吨美利曲辛片对冠心病患者焦虑、抑郁症状的影响.方法 将明确诊断为冠心病伴焦虑、抑郁症状的120例随机分为治疗组(63例)和对照组(57例)两组,均予心理干预及常规治疗,治疗组同时口服氟哌噻吨美利曲辛片治疗.治疗2周后比较两组临床症状缓解情况,焦虑自评量表(SAS)、抑郁自评量表(SDS)评分及心律失常变化情况.结果 治疗后两组SAS、SDS评分均较治疗前显著下降,差异有统计学意义(P＜0.05);治疗组较对照组下降更为明显,差异亦有统计学意义(P＜0.05).治疗后治疗组胸痛等临床症状的缓解率明显高于对照组,差异有统计学意义(P＜0.05).24 h动态心电图检查结果示治疗组室性期前收缩治疗前为(834.8±396.7)/24 h,治疗后为(638.5±232.0)/24 h,治疗前后比较差异有统计学意义(P＜0.05).结论 氟哌噻吨美利曲辛片能显著改善冠心病患者的焦虑、抑郁症状,并缓解胸痛,且短期内无增加心律失常的风险.
展开▼
